Last reviewed · How we verify
NCT03549143: ROMERUS
Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation
trial testing IBS in Irritable Bowel Syndrome in 1,000 participants. Completed in 19 April 2019.
19 April 2019
Quick facts
| Lead sponsor | Abbott |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 25 December 2017 |
| Primary completion | 19 April 2019 |
| Estimated completion | 19 April 2019 |
| Sites | 37 locations across Russia |
Drugs / interventions tested
- IBS
Conditions studied
- Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
Sponsor
Abbott — full company profile →
Who can join
Adults 18 to 50, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03549143
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Irritable Bowel Syndrome
Currently open trials in the same condition.
- NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
- NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting
Other Abbott trials
Trials by the same sponsor.
- NCT06217393 — Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia · Phase 3 · completed
- NCT05370703 — A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treat · completed
- NCT05519514 — Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects · Phase 1 · completed
- NCT04784208 — A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY) · unknown
- NCT05175131 — Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03549143 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abbott
- Last refreshed: 25 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03549143.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing